Alan L King

6514501, Feb 4, 2003

Dec 21, 1999

09/468517

Eileen P. Kelly - Takoma Park MD
Alan D. King - Washington DC

The United States of America as represented by the Secretary of the Army - Washington DC

A61K 3912

4242181, 4241851, 4241861, 4241921, 4242021, 4242041, 435 693, 4352351, 4353201, 536 2372

A recombinant protein encompassing the complete envelope glycoprotein and a portion of the carboxy-terminus of the membrane/premembrane protein of dengue 2 virus was expressed in baculovirus as a protein particle. The recombinant protein particle was purified and found to provide protection against lethal challenge with dengue 2 virus in mice.

6603998, Aug 5, 2003

Jul 30, 2001

09/889581

Alan D. King - Takoma Park MD
Richard E. Walters - Columbia MD

Cyto Pulse Sciences, Inc. - Hanover MD

A61N 130

604 20, 604501

An object of the invention is to provide a method for delivery of macromolecules into biological cells, such as Langerhans cells ( ) in the epidermis ( ) of a patient, which includes the steps of coating electodes ( ) in an electrode assembly ( ) with solid phase macromolecules to be delivered, such as a DNA, and/or RNA vaccine or a protein-based vaccine, attaching the electrode assembly ( ) having the coated electrodes ( ) to an electrode assembly holder ( ), providing a waveform generator ( ), establishing electrically conductive pathways between the electrodes ( ), and the waveform generator ( ), locating the electrodes ( ) such that the biological cells are situated therebetween, such as by penetrating the needle electrode ( ) into the epidermis ( ) above the epidermal basal lamina, and providing pulse waveform from the waveform generator ( ) to the electrodes ( ), such that macromolecule on the electrodes ( ) is driven off of the electrodes ( ), and delivered into the biological cells, such as the Langerhans cells ( ).

6653114, Nov 25, 2003

Oct 7, 2002

10/265133

Richard E. Walters - Columbia MD, 21045
Alan D. King - Takoma Park MD, 20912
Derin C. Walters - Austin TX, 78758-3321

C12N 1300

4351736, 4351734, 4351735, 205701

The object of the invention is to provide a method and apparatus for treating membrane-containing material with electrical fields, in vitro, and with an added treating substance. With the method, a plurality of electrodes are arrayed around the material to be treated and are connected to outputs of an electrode selection apparatus. Inputs of the electrode selection apparatus are connected to outputs of a pulse sequence generator. A treating substance is added to the membrane-containing material. Electrical pulses are applied to the electrode selection apparatus and are routed through the electrode selection apparatus in a predetermined, computer-controlled sequence to selected electrodes in the array of electrodes, whereby the membrane-containing material is treated with the added treating substance and with electrical fields. The routing of applied pulses through the electrode selection apparatus to selected electrodes can be done in an enormous number of ways.

6713291, Mar 30, 2004

Aug 3, 2001

09/920861

Alan D. King - Takoma Park MD, 20912
Richard E. Walters - Columbia MD, 21045

C12N 1300

4351736

An object of the invention is to provide a method for delivery of macromolecules into biological cells in the tissues of a patient and includes the steps of: (a) providing electrodes ( ) in an electrode assembly ( ), wherein the electrodes have fixed electrode surfaces ( ) which are coated with at least one static layer of electrode releasable molecules ( ) to be delivered; (b) providing a waveform generator ( ) for generating electric fields; (c) establishing electrically conductive pathways between the electrodes ( ) and the waveform generator ( ); (d) locating the electrodes ( ) such that the biological cells are situated therebetween, and (g) providing electric fields in the form of pulse waveforms from the waveform generator ( ) to the electrodes ( ), such that molecules in the at least one static layer of the electrode releasable molecules ( ) on the electrodes ( ) are delivered into the biological cells. The electrode releasable molecules ( ) can be either electric field separable molecules and/or solvent separable material. Another object of the invention is to provide an apparatus for carrying out the method of the invention.

6916656, Jul 12, 2005

Apr 5, 2002

10/487235

Richard E. Walters - Columbia MD, US
Derin C. Walters - Columbia MD, US
Alan D. King - Highland MD, US

Cyto Pulse Sciences, Inc. - Glen Burnie MD

C12N015/02
C12N015/64

435450, 435461, 435470, 435471

An object of the invention is to provide a method of treating biological cells prior to subjecting the biological cells to cell fusion pulses which includes the step of treating the biological cells with pre-fusion electric field waveforms which change amplitude in a non-linear way with respect to time, such that the biological cells are first aligned with a relatively low amplitude, long duration pre-fusion electric field waveform and then compressed with a relatively high amplitude, short duration pre-fusion electric field waveform resulting in increased cell membrane contact prior to being subjected to cell fusion. The non-linear pre-fusion electric field waveforms can change in a stepped way, in a continuous way, in a sigmoidal way, with step-wise increasing waveforms in adjacent steps, with step-wise increasing waveforms in non-adjacent steps, and in accordance with non-linear algorithms.

7265215, Sep 4, 2007

Feb 3, 2003

10/357129

Eileen P. Kelly - Takoma Park MD, US
Alan D. King - Washington DC, US

United States of America as Represented by the Secretary of the Army - Washington DC

C07H 21/00
A61K 39/12

536 231, 4242181

A recombinant protein encompassing the complete envelope glycoprotein and a portion of the carboxy-terminus of the membrane/premembrane protein of dengue 2 virus was expressed in baculovirus as a protein particle. The recombinant protein particle was purified and found to provide protection against lethal challenge with dengue 2 virus in mice.

8293701, Oct 23, 2012

Jun 21, 2006

11/922633

Christoph Leder - Wendisch Evern, DE
Alan D. King - Highland MD, US
Maxim Pavlenko - Moscow, RU
Pavel Pisa - Basel, SE

Cellectis S.A. - Paris

A01N 37/18

514 11, 514 195

An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e. g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen.

20040203124, Oct 14, 2004

Mar 29, 2004

10/810829

Alan King - Takoma Park MD, US
Richard Walters - Columbia MD, US

C12N013/00
C12N015/01

435/173600, 435/446000

An object of the invention is to provide a method for delivery of macromolecules into biological cells in the tissues of a patient and includes the steps of: (a) providing electrodes () in an electrode assembly (), wherein the electrodes have fixed electrode surfaces () which are coated with at least one static layer of electrode releasable molecules () to be delivered; (b) providing a waveform generator () for generating electric fields; (c) establishing electrically conductive pathways between the electrodes () and the waveform generator (); (d) locating the electrodes () such that the biological cells are situated therebetween, and (g) providing electric fields in the form of pulse waveforms from the waveform generator () to the electrodes (), such that molecules in the at least one static layer of the electrode releasable molecules () on the electrodes () are delivered into the biological cells. The electrode releasable molecules () can be either electric field separable molecules and/or solvent separable material. Another object of the invention is to provide an apparatus for carrying out the method of the invention. The static-coated electrode assembly () can be provided in a sterile package (), from which the electrode assembly () is removed prior to use. The statically-coated electrode assembly () can be in a form of a disposable assembly () which is removable and replaceable from an electrode assembly holder ().